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ABSTRACT The type I interferon (IFN) system represents an essential innate immune
response that renders cells resistant to virus growth via the molecular actions of IFN-
induced effector proteins. IFN-mediated cellular states inhibit growth of numerous and
diverse virus types, including those of known pathogenicity as well as potentially emerg-
ing agents. As such, targeted pharmacologic activation of the IFN response may repre-
sent a novel therapeutic strategy to prevent infection or spread of clinically impactful vi-
ruses. In light of this, we employed a high-throughput screen to identify small molecules
capable of permeating the cell and of activating IFN-dependent signaling processes.
Here we report the identification and characterization of N-(methylcarbamoyl)-2-{[5-(4-
methylphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-2-phenylacetamide (referred to as C11), a novel
compound capable of inducing IFN secretion from human cells. Using reverse genetics-
based loss-of-function assays, we show that C11 activates the type I IFN response in a man-
ner that requires the adaptor protein STING but not the alternative adaptors MAVS and TRIF.
Importantly, treatment of cells with C11 generated a cellular state that potently blocked rep-
lication of multiple emerging alphavirus types, including chikungunya, Ross River, Venezuelan
equine encephalitis, Mayaro, and O’nyong-nyong viruses. The antiviral effects of C11 were
subsequently abrogated in cells lacking STING or the type I IFN receptor, indicating that they
are mediated, at least predominantly, by way of STING-mediated IFN secretion and subse-
quent autocrine/paracrine signaling. This work also allowed characterization of differential an-
tiviral roles of innate immune signaling adaptors and IFN-mediated responses and identified
MAVS as being crucial to cellular resistance to alphavirus infection.
IMPORTANCE Due to the increase in emerging arthropod-borne viruses, such as chi-
kungunya virus, that lack FDA-approved therapeutics and vaccines, it is important to
better understand the signaling pathways that lead to clearance of virus. Here we show
that C11 treatment makes human cells refractory to replication of a number of these vi-
ruses, which supports its value in increasing our understanding of the immune response
and viral pathogenesis required to establish host infection. We also show that C11 de-
pends on signaling through STING to produce antiviral type I interferon, which further
supports its potential as a therapeutic drug or research tool.
KEYWORDS chikungunya virus, IRF3, interferon, Mayaro virus, O’nyong-nyong virus,
Ross River virus, STING, Venezuelan equine encephalitis virus, alphavirus, antiviral
agents
Received 2 November 2017 Accepted 12 
December 2017
Accepted manuscript posted online 20 
December 2017
Citation Gall B, Pryke K, Abraham J, Mizuno N, 
Botto S, Sali TM, Broeckel R, Haese N, Nilsen A, 
Placzek A, Morrison T, Heise M, Streblow D, 
DeFilippis V. 2018. Emerging alphaviruses are 
sensitive to cellular states induced by a novel 
small-molecule agonist of the STING pathway. 
J Virol 92:e01913-17. https://doi.org/10.1128/
JVI.01913-17.
Editor Julie K. Pfeiffer, University of Texas 
Southwestern Medical Center
Address correspondence to Victor DeFilippis, 
defilipp@ohsu.edu.
B.G. and K.P. contributed equally to this article.
The type I interferon (IFN) system is a rapidly mobilized line of defense againstinvading microbes that initiates and directs cellular and systemic processes to
eliminate pathogenic threats. Type I IFNs are secreted cytokines that include IFN- and 
multiple IFN- subtypes that engage the IFN-/ receptor (IFNAR) present on nearly all 
cells (1). Intracellular signaling that ensues involves phosphorylation of signal trans-
ducer and activator of transcription 1 and 2 (STAT1/2) via Janus kinases (JAKs) and leads 
to transcription of myriad IFN-stimulated genes (ISGs). These encode immunologically 
active proteins, including direct antiviral effectors (2) exhibiting molecular functions 
that impair multiple cell-based processes essential to replication of diverse viruses, and 
are ultimately required for clearance of infection (3). Importantly, the type I IFN system 
in vertebrates represents a mechanism to block the intrahost growth of viruses across 
broad taxonomic classes and irrespective of their pathogenic potential. IFN-stimulated 
cellular states are thus refractory to replication by both known and unknown virus 
types, including those that are potentially zoonotic or emerging. Pharmacologic stim-
ulation of IFN processes is therefore being investigated as an antiviral strategy that may 
bestow clinically impactful broad-spectrum outcomes, especially during outbreaks of 
unidentified agents (4).
IFN synthesis is initially triggered following detection of pathogen- or danger-
associated molecular patterns (PAMPs and DAMPs, respectively) by germ line-encoded 
pattern recognition receptor (PRR) proteins. PAMPs and DAMPs are biochemically diverse 
and include structural components of microbes as well as biosynthetically derived mole-
cules, such as nucleic acids and cyclic dinucleotides (CDNs) (5). PRRs upstream of IFN 
transcription include transmembrane Toll-like receptors (TLRs) of double-stranded RNA 
(dsRNA) (TLR3) or bacterial lipopolysaccharide (LPS) (TLR4) as well as cytoplasmic sensors, 
such as RIG-I-like receptors (RLRs) of dsRNA and cytoplasmic dsDNA receptors (CDRs) (6, 7). 
PRR engagement leads to induction of phosphorylation- and ubiquitination-driven signal-
ing that activates transcription factors, such as IFN regulatory factor 3 (IRF3) and nuclear 
factor B (NF-B), that are essential to synthesis of mRNAs encoding IFN- and proinflam-
matory cytokines/chemokines as well as antimicrobial effectors (8, 9). Importantly, canonical 
PRR-induced pathways involve specific adaptor proteins that integrate upstream signals 
from particular receptors and impart degrees of specificity to the resultant transcriptional 
program (10) in ways that are poorly understood. Key adaptors of IRF3/IFN-terminal 
pathways include mitochondrial antiviral signaling protein (MAVS; also called IPS-1, VISA, 
and CARDIF), which is necessary for the dsRNA-dependent PRRs RIG-I and MDA5 (11); TIR 
domain-containing adaptor inducing IFN- (TRIF; also called TICAM1), which is utilized by 
TLR3 and TLR4 (12); and STING (also called MITA, ERIS, and TMEM173), which is both an 
endoplasmic reticulum-associated PRR for CDNs (13) and an adaptor for CDRs (14). MAVS, 
TRIF, and STING activate the kinases IKK and TBK1, which activate NF-B and IRF3, 
respectively (15). Individual stimuli can engage multiple PRR-adaptor pathways and thus 
generate responses that are complex and surprisingly unexplored (16, 17). Moreover, 
synthetic small molecules have been identified that stimulate these processes with great 
precision and elicit IFN-mediated immunotherapeutic effects, including impairment of virus 
replication (18–23).
Mosquito-transmitted alphaviruses are members of the Togaviridae family that are 
distributed widely throughout the globe and have historically demonstrated a ten-
dency to spontaneously emerge in susceptible human populations (24, 25). This is best 
exemplified by chikungunya virus (CHIKV), which was first described in 1953 but 
reemerged dramatically in 2004, causing massive epidemics on islands of the Indian 
Ocean and the Indian mainland and eventually spreading to the New World in 2013 
(26). Emergent outbreaks in recent history have also been documented for infections 
with other alphaviruses, including Venezuelan equine encephalitis virus (VEEV) (27), 
Ross River virus (RRV) (28), Mayaro virus (MAYV) (29), and O’nyong-nyong virus (ONNV)
(30). Clinical manifestations of infections with alphaviruses evolutionarily derived from 
the Old World (CHIKV, RRV, ONNV, and MAYV) primarily include an acute febrile episode 
followed by polyarthralgia and myalgia that can be severe and long lasting (reviewed 
in reference 31). Infections with New World alphaviruses, such as VEEV, are also febrile
but can lead to severe and often fatal neurologic disease, including encephalitis (32). 
Importantly, there currently exist no FDA-approved antiviral drugs or vaccines to 
prevent alphavirus-associated disease.
Alphaviruses exist as enveloped particles that contain a positive-sense, single-
stranded RNA genome encoding four nonstructural and five structural proteins (33). 
Infection of host cells is associated with a rapid and strong induction of innate signaling 
pathways, including those leading to activation of IRF3 (34, 35). This occurs through 
detection of virus-associated dsRNA by cytoplasmic PRRs, such as RIG-I and MDA5, 
which signal to IRF3 via MAVS (34, 36–38), as well as through protein kinase R (PKR), 
which inhibits the cellular translational machinery through phosphorylation-based 
inactivation of eukaryotic initiation factor 2 (34, 39). Despite this, alphaviruses are 
extremely susceptible to the effects of type I IFNs and replicate poorly in cells in which 
an IFN-induced state has been elicited (reviewed in references 40 and 41). To coun-
teract these effects, these viruses have evolved mechanisms to globally inhibit synthe-
sis of cellular mRNAs and proteins, especially those stimulated by IFN-dependent 
signaling (reviewed in reference 42). As such, IFN exhibits its optimal antiviral effect 
when the cytokine is exposed to target cells prior to viral entry. Importantly, direct 
susceptibility to IFN-induced cellular states is documented for CHIKV, VEEV, MAYV, 
ONNV, and RRV. Based on this, we decided to pursue a unique approach to investigate 
the sensitivity of emerging alphavirus types to innate stimulation via IRF3/IFN-terminal 
pathways. For this purpose, we explored the phenotypes and host targets of a novel 
small molecule that activates innate immune responses in human cells. In addition to 
representing a molecular tool for investigating the impact of innate immune stimula-
tion on alphavirus replication, this may also lead to development of new antiviral drugs 
or therapeutic strategies for viral control.
RESULTS
C11 is a small molecule that induces type I IFN-dependent luciferase activity in 
human fibroblast and myeloid cell lines. To identify novel small molecules capable 
of activating the type I IFN response in human cells, we employed a high-throughput 
screening assay developed using telomerase-transduced foreskin fibroblasts (THF) that 
were stably transduced with green fluorescent protein (GFP) and luciferase (LUC) 
reporter proteins responsive to IFN-induced, ISRE-dependent signaling (18, 43). Exam-
ination of approximately 52,000 chemically diverse molecules in duplicate led to 
identification of N-(methylcarbamoyl)-2-{[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-
2-phenylacetamide, which we have termed C11, as the most potent overall hit. We next 
confirmed the screening results in THF and myeloid-derived MonoMac6 (MM6) cells 
transduced with the ISRE-LUC reporter (THF-ISRE and MM6-ISRE cells, respectively) and 
examined whether the LUC signal correlated with the molecule’s dose. As shown in Fig. 1A, 
LUC activity in THF-ISRE cells exceeded the background at 25 M C11 and increased 
proportionally to dosage, to a maximum of approximately 60-fold. LUC activity in MM6-ISRE 
cells exceeded the background at 50 M C11 and increased to 50-fold above that for mock 
treatments at 100 M C11 (Fig. 1B). Importantly, cell viability as determined by ATP release 
was not significantly affected at any concentration after 24 h (Fig. 1A and B).
Next, we examined the ability of C11 to elicit innate reactivity in nonhuman cells. For 
this purpose, we utilized murine RAW264.7 monocytic cells stably transduced with an 
ISRE-LUC reporter cassette as shown in Fig. 1C. While the mouse-specific IFN-inducing 
molecule DMXAA (5,6-dimethylxanthenone-4-acetic acid) was able to trigger a sub-
stantial LUC signal in these cells, no induction was seen with any dose of C11. Since C11 
elicited responses in myeloid-derived MM6 cells, we next asked whether another 
human monocytic cell line reacts similarly to the compound. Surprisingly, phorbol 
myristate acetate (PMA)-differentiated THP-1 cells stably transduced with an IFN-
dependent reporter responded to transfection with 2=3=-cGAMP but not to treatment 
with C11 (Fig. 1D). These results indicate that the molecule does not activate an innate 
immune response in murine cells or THP-1 cells but does so in human fibroblasts and 
MM6 cells. This suggests that the host factors targeted by the molecule that lead to
FIG 1 Dose-dependent activation of type I interferon-mediated signaling and cytotoxicity of C11. The top graphs show
ISRE-dependent expression of luciferase (LUC) as well as percent cellular viability as determined by CellTiter-Glo assay for THF
(A) and MM6 (B) cells and ISRE-dependent expression of LUC in RAW264.7 (C) and THP-1 (D) cells (the x axis represents the
C11 concentration in micromolar units). Cells were exposed to C11 at the indicated concentrations (micromolar), 10 g/ml
2=3=-cGAMP, or 50 M DMXAA for 8 h (LUC assay) or 24 h (CellTiter-Glo assay). Values presented are mean fold changes and
standard deviations (SD) relative to the values for cells treated with 1% DMSO (black bars; left y axis). Cell viability data are
expressed as percentages of the signal detected in DMSO-treated cells (gray squares; right y axis). Values displayed are based
on three replicates. (E) Chemical structure of N-(methylcarbamoyl)-2-{[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-2-
phenylacetamide (C11). The graph shows luminescence from THF-ISRE cells following 8 h of exposure to multiple concen-
trations of the indicated C11 derivative molecules, with structures shown below the graph. Values presented are average fold
changes and SD for duplicates relative to the values for DMSO-treated cells.
IFN-dependent activity either are lacking in nonresponsive cells or exist as variants that 
are nonreactive to C11 stimulation. These are discussed in more detail below. To obtain 
knowledge about C11’s structure-activity relationship (SAR), such as which moieties 
may be essential to the compound’s innate activity, we next synthesized 10 analogs of 
the molecule that differed from the original at various positions (Fig. 1E). THF-ISRE cells 
were exposed to these analogs at 12.5, 25, 50, or 100 M for 8 h, and LUC activities 
were measured. Unfortunately, all of the chemical alterations we attempted led to 
abrogation of innate immune stimulation by the derivatives. These results suggest that 
either the structure of C11 is chemically optimal for innate immune activation or the 
modifications made were qualitatively inconsistent with maintaining the compound’s 
innate stimulatory capacity. To address this, additional analogs could be synthesized 
and tested as described here.
C11 induces transcription and translation of interferon-dependent antiviral 
genes. Since C11 triggered expression of a heterologous ISRE-dependent reporter 
protein, we next asked whether it was also able to induce transcription of endogenous 
host genes, including type I IFN genes and ISGs. As shown in Fig. 2A, treatment of THF 
cells with C11 led to upregulation of Viperin (RSAD2) and IFIT1 mRNAs to levels similar 
to those induced by treatment with IFN- or the IFN-inducing RNA virus Sendai virus 
(SeV). Moreover, C11 also induced expression of IFN- itself, a result consistent with 
observed ISG induction. Interestingly, transfection with 2=3=-cGAMP, the endogenous 
ligand for the STING protein, also triggered transcription of IFN- but induced sub-
stantially higher levels of IFIT1 and Viperin, suggesting differential activation processes
FIG 2 C11 induces transcription and translation of IFN- but not NF-B-dependent genes. Average fold changes and SD (relative to the values for cells treated
with 1% DMSO) for duplicate experiments are shown for IFIT1, Viperin, and IFN- (A) or IL-1, IL-6, and IL-8 (B) mRNAs in THF cells following 6 h of exposure
to IFN- (1,000 U/ml), SeV (160 HAU/ml), cGAMP (10 g/ml), or C11 (50 M or 100 M). (C) Average fold changes and SD (relative to the values for cells treated
with 1% DMSO) for duplicate experiments for IFIT1 and Viperin mRNAs in human PBMC following 8 h of exposure to 1% DMSO, 10 g/ml 2=3=-cGAMP, or C11
(50 M or 100 M). (D) Secretion of bioactive type I IFN from MM6 and THF cells treated in triplicate overnight with 1% DMSO, C11 (50 M), or UV-inactivated
CMV (MOI  3). Data are expressed as average levels and SD for type I IFN equivalents. (E) Immunoblots (IB) of whole-cell lysates of THF-ISRE cells following
8 h of exposure to 1% DMSO, IFN- (1,000 U/ml), or C11 (50 M or 100 M), as indicated, showing protein levels of Mx1, ISG15, and GAPDH.
by or cellular sensitivity to these stimuli. Synthesis of IFN- mRNA often correlates with 
that of proinflammatory genes due to the involvement of PRR-induced signaling 
pathways that activate transcription factors required for both, such as IRFs and NF-B 
(8, 44). We therefore examined expression of interleukin-1 (IL-1), IL-6, and IL-8 in 
these cells in response to C11 treatment. As shown in Fig. 2B, the molecule failed to 
induce significant levels of mRNAs for these genes, in contrast to SeV, indicating a likely 
disparity in the proinflammatory signaling pathways triggered by these stimuli. Intrigu-
ingly, however, while 2=3=-cGAMP did not induce detectable IL-1 or IL-8 mRNA 
synthesis, it led to very high levels of IL-6 mRNA, a phenomenon not previously 
described, to our knowledge. We next asked if C11 would induce the transcription of 
ISGs in primary human cells by treating human peripheral blood mononuclear cells 
(PBMC). As shown in Fig. 2C, the compound similarly activated expression of ISGs in 
these cells, indicating that its stimulatory capacity is evident in cells beyond those with 
extended life.
Since IFN-dependent proteins are ultimately responsible for conferring antiviral 
phenotypic effects, we next examined the translation of C11-associated genes. We first 
confirmed that C11 was able to elicit secretion of bioactive type I IFN in THF and MM6 
cells. As shown in Fig. 2D, exposure of THF and MM6 cells to 50 M C11 resulted in 
significant levels of functional type I IFN in the culture media, as did the control 
stimulus, human cytomegalovirus rendered inactive by UV irradiation (UV-CMV). In 
addition, C11 exposure also led to translation of ISG proteins Mx1 and ISG15 (Fig. 2E), 
both known to confer potent antiviral activity (45–47). As such, we concluded that C11
is able to trigger transcription and translation of type I IFN genes, as well as canonical
ISGs, but not those of proinflammatory genes.
FIG 3 C11 induces IRF3 phosphorylation and ISG transcription in a manner that requires STING but is independent of MAVS, TRIF, or CDRs. (A) Immunoblots
of whole-cell lysates of THF-ISRE cells following 4 h of exposure to 1% DMSO, IFN- (1,000 U/ml), SeV (160 HAU/ml), LPS (10 g/ml), 2=3=-cGAMP (10 g/ml),
or C11 (75 M), as indicated, showing the phosphorylation status of IRF3 S386, total IRF3, and GAPDH. (B) Immunoblots of whole-cell lysates showing
phosphorylation status of IRF3 S386 and total IRF3 for wild-type THF cells pretreated for 2 h with DMSO or BX795 (TBK1 inhibitor; 10 M) and then stimulated
with C11 (75 M) for 4 h. (C) Immunoblots of whole-cell lysates of cells lacking TRIF, MAVS, or STING following 4 h of exposure to 1% DMSO, SeV (160 HAU/ml),
LPS (10 g/ml), 2=3=-cGAMP (10 g/ml), UV-CMV (MOI  3), or C11 (75 M), as indicated, showing phosphorylation status of IRF3 S386, total IRF3, and GAPDH.
(D) Average fold changes and SD (relative to the values for cells treated with 1% DMSO) for duplicate experiments for IFIT1 and Viperin mRNAs in THF cells
lacking TRIF, MAVS, or STING following 8 h of exposure to the indicated treatments, as described above. (E) Melting temperature shifts for human STING-CTD
in the presence of DMSO, 100 M C11, or 200 M 2=3=-cGAMP. RLU, relative light units. (F) (Left) Immunoblot showing presence or absence of cGAS, DDX41,
or IFI16 protein in each THF-ISRE cell line, as well as GAPDH as a loading control. (Right) Luminescence from WT parental THF-ISRE cells as well as that from
cells with deletions created using CRISPR/Cas9 technology. Values presented are average fold changes and SD for duplicates relative to the value for
DMSO-treated cells.
C11 induces canonical IRF3 phosphorylation and ISG transcription in a manner 
that requires STING but not MAVS or TRIF. Transcription of IFN- requires IRF3 in an 
activated form, as indicated by the phosphorylation of C-terminal serine residues that 
occurs via the kinase TBK1 (48). Since C11 induces IFN secretion and ISG transcription, 
we predicted that it would also trigger phosphorylation of IRF3 via this mechanism, as 
do other established IFN-inducing stimuli. As shown in Fig. 3A, exposure of THF cells to 
canonical IRF3-terminal PAMPs, such as SeV (MAVS agonist), LPS (TRIF agonist), and 
2=3=-cGAMP (STING agonist), led to phosphorylation of IRF3 S384 by 4 h postinfection. 
Likewise, C11 triggered a similar response, indicating that the molecule also stimulates 
an innate signaling reaction that leads to IRF3 activation. Next, to verify that C11 
activates the TBK1-IRF3 axis, we pretreated THF cells with BX795, a small-molecule
inhibitor of TBK1 (49), prior to cotreatment with C11. BX795 treatment resulted in nearly 
complete suppression of IRF3 phosphorylation, indicating that C11 triggers canonical 
TBK1-dependent phosphorylation of IRF3 (Fig. 3B).
TBK1-mediated IRF3 phosphorylation occurs in response to one or more activated 
signaling cascades defined by the adaptor proteins MAVS, TRIF, and STING (reviewed in 
reference 10). To determine the target pathway stimulated by C11 upstream of TBK1, 
we tested whether C11-mediated IRF3 activation requires any of these adaptors by 
employing three THF cell lines, each lacking a single adaptor protein, to perform 
loss-of-function assays (18, 43). As illustrated in Fig. 3C, cells lacking TRIF or MAVS failed 
to exhibit IRF3 phosphorylation in response to established stimuli of those specific 
adaptors (LPS and SeV, respectively), therein functionally demonstrating the absence of 
the proteins. However, IRF3 phosphorylation was observed in both cell types following 
exposure to C11, suggesting that the molecule activates a pathway(s) that requires 
neither protein or requires either MAVS or TRIF in a redundant manner. However, while 
cells lacking STING exhibited IRF3 phosphorylation in response to TRIF- and MAVS-
specific stimuli (LPS and SeV), no such reactivity was observed following exposure to 
UV-inactivated cytomegalovirus (a demonstrated STING agonist [50]) or C11. These 
observations both verify the absence of STING-mediated signaling in these cells and 
indicate that C11 requires a STING-inclusive pathway for its phosphorylation of IRF3.
We next examined synthesis of ISG mRNAs (IFIT1 and Viperin) in these cells to 
validate that their transcription correlates with expected responses based on IRF3 
activity. As shown in Fig. 3D, all cell types transcribed IFIT1 and Viperin in response to 
IFN-, indicating that the IFN-dependent JAK/STAT pathways were intact in all cases. 
Moreover, exposure to canonical activators of the adaptors encoded by the cells also 
led to ISG induction as evidence that those pathways were also functional. As expected, 
stimuli specific for pathways defined by the deleted proteins failed to induce signifi-
cantly greater expression of the ISGs than that with dimethyl sulfoxide (DMSO), functionally 
confirming the absence of each adaptor protein. In agreement with our observations 
regarding IRF3 phosphorylation responses (Fig. 3C), the STING agonist 2=3=-cGAMP and C11 
led to ISG transcription in cells lacking MAVS or TRIF but not STING (Fig. 3D). This result 
provides additional confirmation that STING, but not MAVS or TRIF, is essential to the innate 
signaling response induced by the molecule.
We next examined whether evidence exists that C11 may activate STING-dependent 
processes through direct engagement of the protein. For this purpose, we employed a 
fluorescence-based thermal shift assay on a purified protein consisting of the STING 
C-terminal ligand binding domain (LBD) (43). In this procedure, we expect that direct 
contact between the protein and an interrogated ligand will result in an increase in the 
protein’s thermal stability that is manifested as emission of SYPRO Orange at higher 
temperatures than those in the absence of the ligand. As shown in Fig. 3E, incubation 
of purified STING-LBD with 2=3=-cGAMP led to an obvious increase in the temperature 
at which fluorescence was emitted relative to that with DMSO alone. However, the 
presence of C11 did not lead to a detectable change in fluorescence emission relative 
to that induced by DMSO. This observation is inconsistent with C11 directly interacting 
with STING-LBD as 2=3=-cGAMP does.
Given that C11 is unlikely to act as a direct STING ligand, we next asked whether the 
molecule may require a STING-dependent PRR for innate immune activation. To 
address this, we used clustered regularly interspaced short palindromic repeat 
(CRISPR)/Cas9 genome editing to construct three THF-ISRE cell lines that singularly lack 
cGAS, DDX41, or IFI16, as illustrated in Fig. 3F. Treatment of each of these cells with 75 
M C11 induced LUC expression that resembled that observed in the wild-type (WT) 
parental cells. Based on this result, we concluded that C11 activates innate immune 
signaling in a manner that requires STING but not cGAS, DDX41, or IFI16, PRRs that have 
been shown to signal by way of STING.
C11-mediated IRF3 and ISG activation occurs in cells lacking both MAVS and 
TRIF. The results presented above indicate that the IRF3/IFN-activating response 
triggered by C11 requires STING but neither MAVS nor TRIF individually. It is still
FIG 4 C11 induces IRF3 phosphorylation and ISG transcription in a manner that is independent of MAVS and TRIF. (A)
Immunoblots of whole-cell lysates for MAVS, TRIF, and GAPDH for parental THF-ISRE (WT) cells as well as derivative cells in
which the MAVS and TRIF proteins were deleted (THF-ISRE-ΔMAVS/TRIF cells) by use of CRISPR/Cas9 technology. (B)
Immunoblots of whole-cell lysates of THF-ISRE-ΔMAVS/TRIF cells following 4 h of exposure to 1% DMSO, SeV, LPS, 2=3=-cGAMP,
UV-CMV (MOI  3), or C11 (75 M), as indicated, showing phosphorylation status of IRF3 S386, total IRF3, and GAPDH. (C)
Synthesis of IFIT1 and Viperin mRNAs in THF-ISRE-ΔMAVS/TRIF cells following exposure to 1% DMSO, 1,000 U/ml IFN-, 160
HAU/ml SeV, 10 g/ml LPS, 10 g/ml 2=3=-cGAMP, or 75 M C11. Values presented are average fold changes and SD for
duplicate experiments relative to the values for cells treated with 1% DMSO.
possible, however, that innate activation by the compound requires either MAVS or 
TRIF as well as STING. Precedents demonstrating essential involvements of both MAVS 
(reviewed in reference 51) and TRIF (52) in specific STING-mediated reactions do exist. 
To address whether C11 activates a STING-inclusive signaling response that requires 
either TRIF or MAVS redundantly, we constructed a THF cell line that lacks both proteins 
(Fig. 4A). As predicted, these cells did not exhibit IRF3 phosphorylation (Fig. 4B) or ISG  
transcription (Fig. 4C) in response to treatment with SeV or LPS, yet they did display 
IRF3 phosphorylation following treatment with 2=3=-cGAMP, indicating that STING-
mediated signaling was operational. Importantly, C11 was also able to activate IRF3 
phosphorylation (Fig. 4B) and ISG induction (Fig. 4C) in these cells. This observation 
supports the conclusion that neither TRIF nor MAVS is redundantly essential in com-
bination with STING for the IRF3-terminal pathway triggered by C11.
C11 elicits a cellular state that inhibits replication of multiple emerging alpha-
viruses. Since exposure of cells to C11 leads to expression of type I IFN and ISGs known 
as antiviral effectors, we next asked whether the compound can generate a cellular 
environment antagonistic to virus growth. For this purpose, we chose to examine 
members of the Alphavirus genus, since they exhibit great sensitivity to the effects of 
IFN (reviewed in references 40 to 42) and are highly clinically relevant based on their 
propensity for spontaneous emergence. We therefore measured growth of CHIKV, 
VEEV, MAYV, RRV, and ONNV on THF cells over a range of C11 concentrations. As shown 
in Fig. 5A, viral titers of each virus decreased significantly with increasing C11 molarity. 
This resulted in 90% effective concentration (EC90) values of 16.44 M for CHIKV, 16.7 
M for VEEV, 18.84 M for ONNV, 25.19 M for MAYV, and 22.57 M for RRV. Titers of 
CHIKV and ONNV dropped over 5 and 4 logs, respectively, to below the limit of 
detection, with 50 M C11. Titers of VEEV and MAYV dropped approximately 4 logs but 
were detectable with 50 M C11. RRV was the least responsive to C11 in terms of titer 
decrease but also grew to the lowest titer of all examined viruses in the absence of the 
compound, a likely effect of its sensitivity to the inherent innate immune capacity of 
THF cells (addressed below). Based on these results, we concluded that C11 elicits 
conditions in THF cells that are potently refractory to growth of multiple alphavirus 
types.
The data in Fig. 5A indicate that C11 prophylactically generates a cellular state that 
is inhibitory to replication of multiple alphavirus types. We next decided to ask if C11 
can impair virus replication on exposure of cells to the compound following infection 
(therapeutic efficacy). For this purpose, we focused on CHIKV and VEEV because (i) they
FIG 5 C11 generates a cellular state inhibitory to replication of multiple alphaviruses in a manner that correlates with 
molecular dose. (A) Average PFU per milliliter  SD for CHIKV, VEEV, RRV, MAYV, and ONNV grown on THF cells in triplicate 
in the presence of the indicated concentrations of C11 added at 2 h preinfection. (B) Average PFU per milliliter  SD for CHIKV 
and VEEV grown on THF cells in triplicate in the presence of 50 M C11 added at the indicated hours postinfection (hpi). 
One-way ANOVA comparisons with Dunnett’s post hoc test were made between C11- and DMSO-treated cells. **, P  0.01; 
***, P  0.001.
displayed the largest titer drops in response to C11 and (ii) they represent both New
and Old World phylogenetic clades. We treated THF-ISRE cells with 50 M C11 6, 0,
2, 4, 6, 12, or 24 h after infection with either CHIKV or VEEV and harvested the medium
at 48 h postinfection for virus titration by plaque assay. As shown in Fig. 5B, the
C11-associated significant inhibition of replication of both viruses was detectable when
the compound was added at up to 12 h postinfection. This suggests that C11-induced
innate factors are inhibitory to the growth of both virus types after virus-cell contact. 
Antiviral effects of C11 require STING and IFNAR but not MAVS or TRIF. 
Examination of the molecular basis of C11-mediated innate immune induction, as
defined by IRF3 activation, IFN secretion, and ISG transcription, revealed that STING, but
not TRIF or MAVS, was essential to this process. Based on this, we hypothesized that
only STING would be required for the observed antiviral activity associated with the
FIG 6 C11-mediated antiviral state is abrogated in cells lacking STING and IFNAR but not in those lacking 
MAVS or TRIF. The graphs show average PFU per milliliter  SD at 48 h postinfection for CHIKV, VEEV, 
RRV, MAYV, and ONNV grown in triplicate on THF cells lacking the indicated proteins and pretreated for 
6 h with 1% DMSO, 1,000 U/ml IFN-, or 50 M C11. Within cell types, statistical significance was 
determined by one-way analysis of variance with Dunnett’s multiple-comparison test. *, P  0.05; 
**, P  0.01; ***, P  0.001. The significance of differences between WT and knockout cells for 1%
DMSO treatment was similarly examined and is indicated with red asterisks.
molecule. Additionally, in the absence of IFN-dependent signaling, IRF3 has been 
shown to be required for the expression of a subset of ISGs that confer antiviral effects
(53–55). Since C11 induced both IRF3 activation and IFN secretion, we therefore also 
asked whether the C11-mediated antiviral state required IFN-dependent JAK/STAT 
signaling. To address these questions, we employed THF cells lacking MAVS, TRIF,
STING, MAVS/TRIF, or the type I IFN receptor (IFNAR) (18). We exposed these to 1%
DMSO, 1,000 U/ml IFN-, or 50 M C11 for 6 h prior to infection. This concentration of
C11 represents approximately 3 times the compound’s EC90 for VEEV and CHIKV, 2.65
times the EC90 for ONNV, 2 times the EC90 for MAYV, and 2.22 times the EC90 for RRV. 
As shown in Fig. 6, IFN- generated a strong antiviral state in all cells except those 
lacking IFNAR, demonstrating that the JAK/STAT signaling pathway is intact except
when the receptor is not present. Next, conditions inhibitory to the growth of all viruses
were observed in response to C11 in cells lacking MAVS, TRIF, or both proteins, 
indicating that these pathways are not essential to the establishment of the antiviral 
effect, in agreement with molecular observations regarding innate activation by the 
molecule (Fig. 3 and 4). Also, consistent with these results, cells lacking STING failed to 
inhibit alphavirus replication in response to 50 M C11 (Fig. 6). Interestingly, the 
antiviral effects of C11 were also abrogated in the absence of IFNAR, suggesting that 
these were conferred (perhaps solely) by type I IFN secreted in response to the 
compound.
To assess the degree to which replication of the different virus types is affected by 
infection-induced type I IFN responses as well as the functions of the various adaptor 
proteins, we examined differences in viral titers between the wild-type cells and the 
described knockouts following control DMSO treatment from this experiment. As 
shown in Fig. 6, all viruses exhibited significantly higher titers in both cell types lacking 
MAVS, an observation consistent with an inhibitory impact of the IFN-inducing activity 
of the MAVS-dependent PRRs RIG-I and MDA5 on innate detection of viral RNA during 
alphavirus infection (34, 36, 37). Consistent with this, cells lacking IFNAR also displayed 
significantly higher replication of CHIKV, VEEV, RRV, and ONNV, suggesting that type I 
IFN signaling contributes substantially to the innate control of these viruses. Oddly, 
MAYV titers appeared to be lower in cells lacking IFNAR. Whether this is related to more 
rapid virus-induced cell death due to a lack of innate immune control in these cells, and 
thus a shorter duration of active virus production, would require more detailed inves-
tigation. Interestingly, the lack of STING and TRIF led to increased titers of RRV, and 
STING’s absence also allowed ONNV to grow to significantly higher titers. Whether 
infection with these viruses triggers pathways dependent on TRIF or STING that then 
generate antiviral cellular states to which they are susceptible is a question outside the 
scope of this study. Overall, these results indicate that MAVS plays a crucial role in the 
innate intracellular response to infection with multiple alphaviruses that is likely 
mediated through infection-associated IFN secretion and IFNAR signaling.
DISCUSSION
Here we describe C11, a novel small molecule identified through a high-throughput 
screening endeavor that activates innate immune signaling in human cells. This re-
sponse includes synthesis and secretion of type I IFN as well as expression of ISGs 
known to confer direct antiviral effects. The molecule is active on fibroblasts, primary 
PBMC, and myeloid-derived MonoMac 6 cells and exhibits insignificant cytotoxic effects 
at concentrations that induce innate activity. The signaling pathway stimulated by C11 
terminates in IRF3 activation, but no clear evidence of NF-B-dependent transcription 
was observed. Cells exposed to C11 exhibited a phenotypic state that was refractory to 
replication of multiple alphavirus types in a manner that required both the adaptor 
protein STING and IFNAR. Additionally, C11 was able to inhibit virus growth when 
added at up to 12 h postinfection, suggesting some therapeutic efficacy.
C11 was originally identified and subsequently validated as effective on telomerase-
transduced human fibroblasts (Fig. 1B). Since these cells merely have extended life via 
telomerase and are not transformed via mutagenesis, they represent a suitable model 
of the innate immune signaling that is often defective in cancerous cell lines (56). 
Importantly, type I IFN responses are fully functional in these cells (57). Furthermore, 
their prolonged life span renders them tractable to transgenic manipulations, such as 
gene knockout or protein overexpression, that rely on multiple passages in the pres-
ence of selecting agents. Finally, they also strongly support growth of alphaviruses (34, 
43) and are thus appropriate for studying antiviral phenotypes. While examining 
whether the compound was efficacious on other human cell types, we measured innate 
activation in the myeloid cell lines MM6 and THP-1. Surprisingly, ISRE-dependent 
transcription was observed in MM6 but not THP-1 cells (Fig. 1). The mechanism 
underlying this disparity is presently unclear but may be causally related to the STING 
allele observed in THP-1 cells (58), which differs from the homozygous WT genotype 
exhibited by THF and MM6 cells (not shown) and is known to exhibit decreased
reactivity to canonical ligands of the protein (59). A transcriptomic comparison of these 
cell types may also reveal potential STING-associated signaling components that differ 
between them and may play crucial roles in C11-induced activity. It was additionally of 
interest whether the molecule elicited innate activity in cells of murine origin given the 
power of in vivo mouse models available for alphavirus study (reviewed in reference 
60). Unfortunately, treatment of murine RAW264.7 cells with C11 did not lead to 
detectable ISRE-dependent LUC activity (Fig. 1C). Whether this is due to the specificity 
of C11 for a human-specific, STING-inclusive pathway will require more exploration.
In an effort to understand the cellular signaling components required for C11-
associated stimulation, we first examined endogenous mRNAs synthesized in response 
to C11 treatment. Transcripts known to be induced by IRF3-dependent processes, such 
as IFN-, IFIT1, and Viperin, were also induced by C11, consistent with the transcription 
factor itself being activated by the compound (Fig. 2). Surprisingly, while stimuli that 
lead to IRF3 activation often also activate NF-B, we failed to observe transcription of 
the genes for IL-1 (61), IL-6 (62), or IL-8 (63), which are conventional genes dependent 
on this transcription factor. We therefore targeted phosphorylation of IRF3 as a primary 
phenotypic readout to investigate C11-induced innate stimulation. As expected, the 
compound triggered phosphorylation of IRF3 S386 via a canonical TBK1-dependent 
mechanism (Fig. 3B). This response is known to occur by way of three distinct pathways, 
defined by the adaptor proteins MAVS, TRIF, and STING (15). We therefore employed 
loss-of-function assays using THF cell lines in which each of the proteins was singly 
deleted by use of CRISPR/Cas9 technology (18, 43). This revealed that C11 was only 
inactive in cells lacking STING (Fig. 3). However, we could not conclude from this result 
whether STING was required in combination with either MAVS (51) or TRIF (52), two 
scenarios that have both been described previously. To address this, we constructed 
THF cells that lacked both TRIF and MAVS but encoded STING. In these cells, C11 
retained its stimulatory properties, indicating that the innate reaction to the compound 
requires STING and functions in the absence of both the TRIF and MAVS adaptor 
proteins (Fig. 4).
The unique essentiality of STING for C11-mediated innate activity is an important 
mechanistic attribute definitive of the molecule’s mode of action. However, the actual 
molecular basis of STING-dependent IRF3/IFN induction in response to C11 may involve 
any number of intracellular targets and physiological apparatuses. For instance, small 
molecules that are direct activating ligands have been described for mouse STING 
isoforms (64–66) but, thus far, not for human orthologs. We asked whether C11 binds 
directly to the STING C-terminal (cytoplasmic) domain (CTD) in an in vitro assay by 
purifying the CTD of the protein and utilizing a fluorescence-based protein thermal shift 
assay (67). As shown in Fig. 3E, incubation of the protein with C11 failed to increase its 
thermal stability, in contrast to incubation with the canonical STING ligand 2=3=-cGAMP. 
While this result is inconsistent with direct engagement of the compound with the 
STING ligand binding domain, it does not formally rule out whether C11 stimulates the 
protein through its transmembrane domain by using an unknown activation mecha-
nism. In addition, it is also possible that interaction between C11 and STING requires 
posttranslational modifications to the protein that occur in mammalian cells but not in 
bacteria used to synthesize the protein, and thus that compound-associated thermal 
shifts are not seen in our assay.
PRRs that require STING for IRF3-terminal signaling have been described before, 
including cGAS (68), IFI16 (69), and DDX41 (70). To determine whether any of these are 
essential to C11-mediated activity, we used CRISPR/Cas9 technology to construct 
THF-ISRE cell lines lacking each. Figure 3F illustrates that the C11-induced ISRE-LUC 
signal is substantial in each of these cell lines, suggesting that the molecule activates 
STING-dependent processes in a manner that does not require any of these PRRs, at 
least individually. It is also possible that C11 acts by way of regulatory cellular proteins 
associated with STING activity. This includes multiple negative regulators, including 
ULK1 (71), NLRX1 (72), and NLRC3 (73), that may represent inhibitory targets of C11. The 
compound may also engage an as yet unknown receptor or signaling molecule that
leads to STING activation. The identity of key host cell targets of C11 may actually be 
ascertainable by way of our observation that the compound induces ISRE signaling in 
MM6 but not THP-1 myeloid-derived cells (Fig. 1). Transcriptomic or proteomic con-
trasts between these cells may lead to identification of factors that are expressed in 
responsive MM6 cells but lacking in THP-1 cells. These could then be explored as 
potential targets by loss-of-function approaches with MM6 cells (e.g., CRSIPR/Cas9) or 
gain-of-function approaches with THP-1 cells.
Intriguingly, although C11 activates STING-dependent signaling, as does the canon-
ical ligand 2=3=-cGAMP, surprising phenotypic differences were observed in cells 
treated with the two stimuli. For example, 2=3=-cGAMP-induced expression of mRNAs 
for IFIT1 and Viperin, but not IFN-, was strongly enhanced over that with other 
IRF3-activating stimuli, including C11, in fibroblasts (Fig. 2A). Moreover, 2=3=-cGAMP 
was also able to trigger high levels of mRNA for IL-6, but not IL-1 or IL-8, in these cells, 
in contrast to C11, which induced none of these transcripts (Fig. 2B). These observations 
are consistent with C11 and 2=3=-cGAMP inducing fundamentally different innate 
signaling pathways, and perhaps transcription factors, in these cells. For example, the 
IL-6 promoter contains binding sites for multiple transcription factors, including AP-1, 
cyclic AMP-responsive element, CCAAT enhancer binding protein , and NF-B (74). It 
is possible that STING activation via 2=3=-cGAMP elicits a quantitatively or qualitatively 
different combination of these factors that manifests as differential gene transcription. 
It is also notable that C11 does not induce transcription of NF-B-dependent genes that 
conventionally are believed to contribute to proinflammatory tissue states (75), sug-
gesting that the compound may represent a more tolerable therapeutic. Understanding 
the molecular basis of these disparities would likely also shed light on the divergent 
and complex roles of STING-dependent IRF3 and NF-B activation (76, 77).
Since C11 elicits the synthesis of type I IFNs (Fig. 2) as well as ISGs (Fig. 2 to 4), we 
predicted that it would correspondingly generate a cellular state unsupportive of virus 
replication. We chose to examine various alphavirus types for which human emergence 
events are documented and thus an unmet clinical need exists. The fact that members 
of this genus exhibit high sensitivity to type I IFNs (reviewed in references 40 and 42) 
provides an additional rationale for the utilization of alphaviruses. As shown in Fig. 5, 
preexposure of wild-type cells to C11 led to multilog reductions in the titer levels of 
CHIKV, VEEV, MAYV, RRV, and ONNV, with CHIKV exhibiting the largest overall titer 
decrease. Interestingly, while C11 was able to significantly inhibit the growth of RRV, 
the overall titer reduction was small, likely due to lower permissivity of fibroblasts to 
RRV replication. Data presented in Fig. 6 support that this is related to anti-RRV effects 
conferred by the type I IFN response, since RRV growth was drastically higher in cells 
lacking an RNA-dependent IFN-inducing (MAVS) or IFN signaling (IFNAR) pathway. The 
loss of C11-mediated antiviral activity in cells that lack STING (but not MAVS, TRIF, or 
both MAVS and TRIF) is consistent with the molecular observations indicating that 
STING is the only canonical adaptor protein involved in the C11-induced signaling 
pathway required for IRF3 activation and ISG expression (Fig. 3 and 4). Furthermore, the 
compound’s antiviral effects were also lost when IFN-mediated JAK/STAT signaling was 
absent due to IFNAR deletion (Fig. 6). Collectively these results indicate that C11 
triggers expression of type I IFN via a STING-dependent process that leads to the 
generation of an IFNAR-mediated antiviral cellular state. Though not specifically ad-
dressed here, it is reasonable to presume that this results from the activities of effector 
proteins encoded by ISGs (78). This result also points to a negligible or absent antiviral 
role for the subset of ISGs that can be expressed in an IRF3-dependent, IFN-
independent manner (53, 54, 79).
An additional finding of this investigation involved the relevance of IRF3-terminal 
adaptor proteins and the alphavirus-induced IFN response to replication of these 
viruses. Relative to parental wild-type cells, all virus types grew to higher titers in cells 
lacking MAVS, the adaptor essential to IFN induction triggered in response to infection 
with RNA viruses, including alphaviruses (34, 36, 37). This result is consistent with a 
crucial antiviral role for this signaling pathway, likely via autocrine/paracrine IFN
signaling as well as a likely IFN-mediated positive-feedback loop that activates tran-
scription of antiviral genes as well as the MAVS-dependent PRRs RIG-I (80) and MDA5 
(81), both of which are crucial for detecting RNA viruses. Ultimately, autocrine IFN 
signaling can reduce viral replication in infected cells, and paracrine signaling can 
establish an antiviral state in uninfected cells. In further support of this, cells lacking 
IFNAR also allowed enhanced replication of CHIKV, VEEV, RRV, and ONNV, a result that 
parallels what has been seen for CHIKV growth in mice that are similarly deficient (82, 
83). Unexpectedly, MAYV replication was not higher in THF-ΔIFNAR cells. It is possible 
that the absence of IFN-dependent activity is responsible for more uncontrolled virus 
replication and cell-to-cell spread, and consequently more rapid cytotoxicity and thus 
lower extracellular virus levels, at this time point (31, 40, 42, 84). Unfortunately, little is 
known about Mayaro virus innate sensitivity and pathogenesis, and alternative exper-
imental conditions, such as an infection time course or kinetic monitoring of cell 
viability during infection, will be needed to understand this observation. An addition-
ally intriguing result was related to the enhancement of the growth of RRV on cells 
lacking either STING or TRIF and the enhancement of that of ONNV on cells lacking 
STING. Since TRIF is downstream of the dsRNA PRR TLR3 (85), it is possible that the 
pathway is activated during RRV infection in a manner that elicits antiviral effects, 
although why this was observed only for this virus will require deeper exploration. 
STING can be activated by viral nucleic acid-independent signaling during RNA virus 
infection, including following virus-cell membrane fusion (86) and in response to 
mitochondrial disruption (87). Whether these or other STING-inducing processes are 
triggered during RRV or ONNV infection, ultimately leading to antiviral effects to which 
these viruses are susceptible, is a possible scenario that warrants examination.
Pharmacologic activation of STING-dependent signaling has shown promise in 
diverse clinically impactful applications, including broad-action antiviral treatments (19, 
23, 43, 88), vaccine adjuvants (89), and immunogenic tumor clearance (90). This has led 
to academic and commercial efforts to formulate CDNs for pharmaceutical use, includ-
ing their advancement to an ongoing clinical trial (NCT02675439). Unfortunately, CDNs 
may be chemically undesirable for research and clinical work because (i) they violate 
the Lipinski rules (91) for druglikeness and are not amenable to large structural 
changes, (ii) they are susceptible to phosphodiesterase-mediated degradation (92), and 
(iii) their size and hydrophilicity render them unable to permeate cell membranes (93). 
Small-molecule STING activators mitigate these factors, as well exemplified by the 
mouse-specific compound DMXAA (64, 65, 94). While other small molecules have been 
shown to induce STING-dependent activity (19, 43, 66, 88), to our knowledge, none 
work in both mice and humans. Novel small-molecule STING agonists that are effica-
cious across species are thus highly sought, as they may lead to valuable research tools 
for work toward understanding STING-mediated processes as well as clinically valuable 
drugs, and their use in animals enables broad assessments of safety and biological 
mechanisms. Our group conducted a high-throughput screen to identify novel com-
pounds that activate IRF3/IFN-dependent processes in human cells. This led to discov-
ery of C11, a molecule that triggers IRF3/IFN-dependent responses in a manner that 
requires STING. To identify a fundamental pharmacophore that is required for the 
compound’s innate activating function, we constructed a group of C11 analogs to 
facilitate characterization of structure-activity relationships (Fig. 1E). Unfortunately, all 
chemical modifications abrogated the molecule’s ability to induce ISRE-LUC expression. 
As such, additional analogs, perhaps displaying more subtle alterations, will be neces-
sary.
In conclusion, we have successfully identified a novel small-molecule agonist of the 
STING pathway that is capable of inducing expression of type I IFNs as well as antiviral 
effector gene products in human cells via IRF3 phosphorylation. Using a CRISPR/Cas9-
driven reverse genetics approach, STING, but not TRIF or MAVS, was shown to be 
required for establishment of an IFN-dependent antiviral state in cells that is effective 
against multiple emerging alphavirus types. These findings further support the poten-
tial therapeutic role for small-molecule agonists of the STING pathway in a number of
diseases, including virus infections and cancers as well as others that have yet to be
identified.
MATERIALS AND METHODS
Reagents and antibodies. Dimethyl sulfide (DMSO) was purchased from Thermo Fisher. Human 
recombinant IFN- was obtained from PBL. Lipopolysaccharide (LPS) was obtained from Sigma. 2=3=-
cGAMP was purchased from Invivogen. Stocks of C11 were originally obtained from Enamine and 
resynthesized in larger quantities by the OHSU Medicinal Chemistry Core Facility. Puromycin was 
obtained from Invivogen and used at 3 g/ml in resistant cell culture. G418 sulfate was obtained from 
Enzo Life Sciences and used at 400 g/ml in resistant cell culture. One-Glo cell lysis/luciferin and 
CellTiter-Glo viability assays were obtained from Promega. Lipofectamine 3000 was obtained from 
Invitrogen. Sources and concentrations of antibodies used against the following antigens are indicated 
in parentheses: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (SC-51906; Santa Cruz) (1:10,000), 
IRF3 (4302; Cell Signaling) (1:1,000), phospho-IRF3 (4947; Cell Signaling) (1:1,000), Mx1 (GTX11153; 
Gentex) (1:2,000), ISG15 (200-401-438; Rockland) (1:2,000), cGAS (15102; Cell Signaling) (1:1,000), DDX41 
(15076; Cell Signaling) (1:1,000), and IFI16 (14970; Cell Signaling) (1:1,000).
Cell and virus cultures. Human foreskin fibroblasts, originally obtained from the American Type 
Culture Collection, were stably transduced with constitutively expressed human telomerase reverse 
transcriptase and the IRF3/IFN-responsive pGreenFire-ISRE lentivector (System Biosciences), sorted, and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 
penicillin (100 U/ml), streptomycin (100 U/ml), HEPES (10 mM), and G418 (400 g/ml). MonoMac6 (MM6) 
cells were a kind gift from Michael Gale (University of Washington) and were transduced with a 
lentivector containing the pGreenFire ISRE cassette. Transduced MM6 cells were then maintained in RPMI 
1640 medium supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 U/ml), HEPES (10 
mM), and G418 (400 g/ml) at a density of 3  105 to 10  105 cells/ml. THP-1 ISG-lucia cells were 
purchased from Invivogen. THP-1 ISG-lucia cells were differentiated by 2 h of  treatment with 100 ng/ml 
PMA, and then the PMA was removed and replaced with complete medium for 72 h of incubation prior 
to all assays. Vero cells were obtained from Alec Hirsch (Oregon Health & Sciences University) and were 
grown as described previously (34). Human peripheral blood mononuclear cells were obtained from 
StemCell Technologies and maintained in RPMI 1640 medium supplemented with 10% FBS, penicillin 
(100 U/ml), streptomycin (100 U/ml), and HEPES (10 mM). All cells were grown at 37°C and 5% CO2. 
Sendai virus (SeV) was obtained from Charles River Laboratories and used at 160 hemagglutination units 
(HAU)/ml. Human cytomegalovirus was grown, titrated, UV inactivated (4 times for 30 s each; 600 kJ), and 
exposed to cells at a multiplicity of infection (MOI) of 3 (pre-UV irradiation). Chikungunya virus (CHIKV) 
was prepared as previously described (18, 43). Venezuelan equine encephalitis virus strain TC83 (VEEV), 
Mayaro virus (MAYV), Ross River virus (RRV), and O’nyong-nyong virus (ONNV) were all obtained from 
Robert Tesh (University of Texas). All viruses were propagated on C6/36 mosquito cells (in DMEM-10%
FBS at 28°C) for 48 h prior to ultracentrifugation, and their titers were determined by serial dilution 
plaque assay on Vero cells. All infections were carried out following 2 h of pretreatment (except where 
otherwise noted) with C11, IFN-, or DMSO at the indicated concentrations, and cells were infected at 
an MOI of 1 PFU per cell. 2=3=-cGAMP was transfected into cells by use of Lipofectamine LTX following 
the manufacturer’s protocol. C11 was added directly to low-serum cell culture medium (2% FBS) for all 
THF cell treatments or to X-Vivo15 defined-serum medium (0% FBS) for all MonoMac6 cell treatments.
CRISPR/Cas9-mediated genome editing. Genome editing using lentivector-mediated delivery of 
CRISPR/Cas9 components was performed generally as described previously (18, 43). For simultaneous 
deletion of TRIF and MAVS, we modified the lentiCRISPRv2 vector (AddGene) (95, 96) by replacing the 
puromycin resistance open reading frame (ORF) with one that confers hygromycin resistance. TRIF-
specific guide RNA (gRNA) was cloned into this vector, which was then used to transduce THF-ISRE-
ΔMAVS cells. The double transfectant was then selected for resistance, serially diluted, and validated for 
the knockout as described previously (18, 43). Sequences of new gRNA targets used here are as follows: 
for DDX41, TGGAGGAGTCGGAACCCGAA; for IFI16, TATACCAACGCTTGAAGACC; and for cGAS, GAACTTT 
CCCGCCTTAGGCA. Lentivirus was made by transfecting the lentivector along with a packaging plasmid 
(psPAX2; AddGene) and a vesicular stomatitis virus G protein pseudotyping plasmid (pMD2.G; Addgene) 
into Lenti-X 293T cells (Clontech) by use of Lipofectamine-LTX (Life Technologies, Inc.). Medium was 
harvested at 48 h and 72 h posttransfection, centrifuged (3,000  g for 10 min), and filtered through a 
0.45-m filter to remove cell debris. Subconfluent target cells were exposed to lentivirus for 8 h in the  
presence of 5 g/ml Polybrene. After target cells reached confluence, cultures were split into DMEM plus 
10% FBS containing 3 g/ml puromycin or 100 g/ml hygromycin. Transduced cells were passaged in 
the presence of selecting agents for 7 to 10 days before protein knockout was examined by immuno-
blotting. Cells were next serially diluted twice in 96-well plates to obtain oligoclonal lines purified for 
gene deletion. Protein knockout was additionally verified functionally by measuring phenotypic respon-
siveness to appropriate stimuli.
Luciferase reporter assay and type I interferon bioassays. For direct THF-ISRE cell reporter assays, 
confluent cells were plated at 20,000 cells/well in a white 96-well plate 24 h before stimulation. 
Treatments were performed in quadruplicate in 40 l of either DMEM plus 2% FBS (THF cells) or X-Vivo15 
medium (MM6 cells) for 8 h, unless otherwise indicated. Steady-Glo lysis/luciferin reagent (Promega) was 
added (1:1 [vol/vol]) to each well, and luminescence was measured on a Synergy plate reader (BioTek). 
For cell viability assays, CellTiter-Glo reagent was used following the manufacturer’s suggested protocol. 
For type I IFN bioassays, cells of interest were plated at 50,000 cells/well in 24-well plates and serum 
starved in either DMEM plus 2% FBS (THF cells) or X-Vivo15 medium (MM6 cells) for 1 h prior to
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treatment. After treatment for 24 h, the medium was harvested and clarified at 10,000  g for 3 min. 
Recombinant IFN- (at 40, 20, 10, 5, 2.5, 1.25, and 0.63 U/ml) was used to generate a standard response 
curve. The supernatant or standard was then added to THF-ISRE-ΔIRF3 cells (do not respond to 
STING/IRF3-inducing stimuli) plated as described above for 8 h, and luminescence was measured. IFN was 
quantitated by curve fitting relative to the signals generated from the standards.
Immunoblotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and im-
munoblotting were performed as follows. After trypsinization and cell pelleting at 2,000  g for 10 min, 
whole-cell lysates were harvested in RIPA lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, and 0.1% SDS) supplemented with Halt protease and phosphatase inhibitor 
cocktail (Thermo Fisher). Lysates were electrophoresed in 8% polyacrylamide gels and then transferred 
onto polyvinylidene difluoride (PVDF) membranes (Millipore) by semidry transfer at 200 mA for 35 min. 
The blots were blocked at room temperature for 2 h or  overnight, using 5% nonfat milk in 1 
phosphate-buffered saline (PBS) containing 0.1% Tween 20. The blots were exposed to primary antibody 
in 5% nonfat milk in 1 PBS containing 0.1% Tween 20 for 18 h at 4°C. The blots were then washed in 
1 PBS containing 0.1% Tween 20 for 20, 15, and 5 min, followed by deionized water for 5 min. A 1-h 
exposure to horseradish peroxidase-conjugated secondary antibodies and subsequent washes were 
performed as described for the primary antibodies. Antibodies were visualized using enhanced chemi-
luminescence (Pierce).
RNA isolation and semiquantitative reverse transcription-PCR. Total RNA was isolated from cells, 
treated with the DNase provided in a DNA-free RNA isolation kit (Zymo Research) according to the 
manufacturer’s protocol, and quantified by using UV spectrometry. Single-stranded cDNA for use as a 
PCR template was made from total RNA and random hexamers to prime first-strand synthesis via a 
RevertAid First Strand cDNA synthesis kit (Thermo Fisher) per the manufacturer’s protocol. Comparison 
of mRNA expression levels between samples was performed using semiquantitative real-time reverse 
transcription-PCR (qPCR) with an Applied Biosystems sequence detection system according to the ΔΔCT 
method (97), with GAPDH as a control. Prevalidated Prime-Time 6-carboxyfluorescein qPCR primer/probe 
sets obtained from IDT were used for all genes.
STING protein purification and thermal shift assays. Assays of the molecular interaction between 
the purified human STING C-terminal domain (CTD) (amino acids 137 to 379; nontransmembrane 
domain) and C11 were performed as previously reported (43). Briefly, the 6His STING CTD open reading 
frame was cloned into pRSET-B (Invitrogen) and used to transform the Escherichia coli strain pLysS 
(Promega). The transformed E. coli cells were then induced to express the 6His STING CTD by use of 
1 mM IPTG (isopropyl--D-thiogalactopyranoside) at 16°C for 18 h. The STING CTD was purified by 
nickel-affinity chromatography (Clontech Laboratories) and then further purified by gel filtration chro-
matography (HiPrep 16/60 Sephacryl S-100 HR column; GE Healthcare Life Sciences). Eluted proteins 
were concentrated using Amicon centrifugal filters (10-kDa cutoff). For thermal shift assays, SYPRO 
Orange dye was used, following the manufacturer’s suggested protocol, to determine protein stability in 
the presence and absence of 2=3=-cGAMP (Invivogen) or C11, as previously described (43).
Statistical analyses. Unless otherwise noted, all data analyses were performed in Prism 6.0, using a 
two-tailed independent t test or one-way analysis of variance (ANOVA), with Bonferroni or Dunnett’s post 
hoc test where indicated. All group variances were confirmed to be nonsignificant by the Brown-Forsythe 
test (P  0.05). Regression analyses of known values of IFN- to interpolate unknown values in IFN 
bioassays were performed using 4-parameter logistic nonlinear regression analyses and confirmed to 
give an appropriate fit (r2  0.90).
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